134 related articles for article (PubMed ID: 28978610)
21. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Hammerness PG; Karampahtsis C; Babalola R; Alexander ME
Expert Opin Drug Saf; 2015 Apr; 14(4):543-51. PubMed ID: 25648243
[TBL] [Abstract][Full Text] [Related]
22. Motor skills of children newly diagnosed with Attention Deficit Hyperactivity Disorder prior to and following treatment with stimulant medication.
Brossard-Racine M; Shevell M; Snider L; Bélanger SA; Majnemer A
Res Dev Disabil; 2012; 33(6):2080-7. PubMed ID: 22796639
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
24. Considerations in the Care of Athletes With Attention Deficit Hyperactivity Disorder.
Pujalte GGA; Maynard JR; Thurston MJ; Taylor WC; Chauhan M
Clin J Sport Med; 2019 May; 29(3):245-256. PubMed ID: 29189334
[TBL] [Abstract][Full Text] [Related]
25. Managing attention-deficit/hyperactivity disorder in children and adolescents.
McClain EK; Burks EJ
Prim Care; 2015 Mar; 42(1):99-112. PubMed ID: 25634708
[TBL] [Abstract][Full Text] [Related]
26. ADHD and pregnancy.
Freeman MP
Am J Psychiatry; 2014 Jul; 171(7):723-8. PubMed ID: 24980168
[TBL] [Abstract][Full Text] [Related]
27. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder.
Biederman J; Seidman LJ; Petty CR; Fried R; Doyle AE; Cohen DR; Kenealy DC; Faraone SV
J Clin Psychiatry; 2008 Jul; 69(7):1150-6. PubMed ID: 18517288
[TBL] [Abstract][Full Text] [Related]
28. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
29. Stimulant medication for ADHD in opioid maintenance treatment.
Abel KF; Bramness JG; Martinsen EW
J Dual Diagn; 2014; 10(1):32-8. PubMed ID: 25392060
[TBL] [Abstract][Full Text] [Related]
30. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design.
Raman SR; Marshall SW; Haynes K; Gaynes BN; Naftel AJ; Stürmer T
Inj Prev; 2013 Jun; 19(3):164-70. PubMed ID: 23143347
[TBL] [Abstract][Full Text] [Related]
31. Does stimulant medication decrease the lower extremity response times of children with and without attention-deficit/hyperactivity disorder?
Brasić JR
Percept Mot Skills; 2007 Feb; 104(1):67-8. PubMed ID: 17450965
[TBL] [Abstract][Full Text] [Related]
32. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
[TBL] [Abstract][Full Text] [Related]
33. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Barner JC; Khoza S; Oladapo A
Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
35. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
[TBL] [Abstract][Full Text] [Related]
36. Attention-deficit/hyperactivity disorder and substance abuse.
Harstad E; Levy S;
Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
[TBL] [Abstract][Full Text] [Related]
37. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.
Zito JM; Safer DJ; dosReis S; Magder LS; Gardner JF; Zarin DA
Arch Pediatr Adolesc Med; 1999 Dec; 153(12):1257-63. PubMed ID: 10591302
[TBL] [Abstract][Full Text] [Related]
38. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.
Mohammadi M; Akhondzadeh S
Acta Med Iran; 2011; 49(8):487-98. PubMed ID: 22009816
[TBL] [Abstract][Full Text] [Related]
39. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895
[TBL] [Abstract][Full Text] [Related]
40. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
